Publications by authors named "Bassem Yamout"

Claim this Profile
M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Bassem Yamout

J Neurol Neurosurg Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region.
Ho Jin Kim, Suzanne J Hodgkinson, Long-Sun Ro, Rocksy Fransisca V Situmeang, Sasitorn Siritho, Bassem Yamout

Mult Scler Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Bassem Yamout

Mult Scler· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Bassem Yamout

J Neurol Neurosurg Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings.
Nick Rijke, Bassem I Yamout, Deanna Saylor, Francesco Nonino, Graziella Filippini

Mult Scler Relat Disord· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Xavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, Georgina Arrambide, Marcello Moccia, Bassem Yamout

Lancet Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent progression independent of relapse activity in multiple sclerosis.
Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Bassem Yamout

Brain Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life and access to treatment for patients with multiple sclerosis during economic crisis: the Lebanese experience.
Maya Zeineddine, Ghida Ismail, Malak Issa, Taghrid El-Hajj, Hassan Tfaily, Bassem Yamout

Qual Life Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Bassem Yamout

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study.
Bassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, Akram M Al-Mahdawi, Samia Joseph Khoury

J Neurol Neurosurg Psychiatry· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Dana Horakova, Eva Kubala Havrdova, Bassem Yamout

CNS Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates.
Jihad Inshasi, Yomna Nowier, Evelina A Zimovetz, Ahmed Moussa, Ahmed Shatila, Bassem Yamout

Ther Adv Neurol Disord· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, Sifat Sharmin, Yi Chao Foong, Bassem Yamout

J Neurol Neurosurg Psychiatry· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update in multiple sclerosis.
Bassem Yamout

eNeurologicalSci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The awareness and knowledge of multiple sclerosis patients about their disease: A Lebanese cross-sectional study.
Maya Zeineddine, Malak Issa, Ghida Ismail, Taghrid El-Hajj, Hassan Tfaily, Bassem Yamout

Mult Scler Relat Disord· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G Chisari, Bassem Yamout

Neurotherapeutics· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Bassem Yamout

Mult Scler· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study.
Daniel Kreiter, Tomas Kalincik, Raymond Hupperts, Francesco Patti, Daniele Spitaleri, Bassem Yamout

CNS Drugs· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice.
Bassem Yamout, Raed Alroughani, Jihad Inshasi, Samar Farouk, Fatema Abdulla

Neurol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.
Maya Zeineddine, Amal Al-Hajje, Pascale Salameh, Joelle Massouh, Georges Saab, Bassem Yamout

Mult Scler Relat Disord· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential diagnosis of suspected multiple sclerosis: global health considerations.
Jorge Correale, Andrew J Solomon, Jeffrey A Cohen, Brenda L Banwell, Fernando Gracia, Bassem Yamout

Lancet Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates.
Anu Jacob, Ahmed Osman Shatila, Jihad Inshasi, Joelle Massouh, Ruquia Mir, Bassem Yamout

Mult Scler Relat Disord· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Bassem I Yamout

Mult Scler· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
Maya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, Samia Khoury, Nabil El-Ayoubi, Bassem Yamout

Mult Scler· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
Tim Spelman, Gabrielle Simoneau, Robert Hyde, Robert Kuhelj, Raed Alroughani, Bassem I Yamout

Neurology· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis